RP
HCAT icon

Riverbridge Partners’s Health Catalyst HCAT Stock Holding History

Riverbridge Partners’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,222,571
Closed -$31.9M – 196
2022
Q1 		$31.9M Buy
1,222,571
+109,115
+10% +$3.1M 0.36% 81
2021
Q4 		$44.1M Buy
1,113,456
+40,825
+4% +$1.86M 0.44% 75
2021
Q3 		$53.6M Sell
1,072,631
-3,826
-0.4% -$209K 0.54% 68
2021
Q2 		$59.8M Buy
1,076,457
+51,747
+5% +$2.76M 0.61% 59
2021
Q1 		$47.9M Sell
1,024,710
-79,957
-7% -$3.87M 0.55% 60
2020
Q4 		$48.1M Buy
1,104,667
+118,965
+12% +$4.39M 0.53% 62
2020
Q3 		$36.1M Buy
+985,702
New +$33.5M 0.5% 66

Other funds holding HCAT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Riverbridge Partners's HCAT Position: Q2 2022 in Review

Riverbridge Partners sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 1,222,571 shares — an estimated $31.9M sold.

Riverbridge Partners first reported a position in HCAT in Q3 2020 and held it in 7 quarters. The position peaked at $59.8M in Q2 2021. 180 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

  • Riverbridge Partners reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
  • Riverbridge Partners sold 1,222,571 Health Catalyst shares in Q2 2022, an estimated $31.9M.
  • Riverbridge Partners first reported a position in Health Catalyst in Q3 2020 and held it in 7 quarters.
  • Riverbridge Partners's Health Catalyst position peaked at $59.8M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on Riverbridge Partners's 13F filing for Q2 2022, filed 11 Jul 2022.